Myomo(MYO) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported full-year revenue of $40.9 million, representing a 26% growth over 2024 [9][25] - Fourth quarter revenue was $11.4 million, the highest quarterly revenue of the year, up 13% sequentially but down slightly year-over-year [25][9] - Gross margin for the fourth quarter was 68.6%, down from 71.4% year-over-year but up from 63.8% in the previous quarter [34][25] - Operating loss for the fourth quarter was $2.8 million, compared to an operating loss of about $200,000 in the prior year quarter [36][37] - Net loss for the fourth quarter was $3.8 million, or $0.09 per share, compared to a net loss of $300,000 or $0.01 per share for the same quarter last year [37][25] Business Line Data and Key Metrics Changes - The U.S. Orthotics and Prosthetics (O&P) channel achieved record quarterly revenue of over $1 million, up 81% year-over-year [32][11] - International revenue reached a record $2.2 million, up 46% year-over-year, primarily driven by growth in Germany [32][15] - The number of MyoPro units ordered in the fourth quarter was 241, up 5% sequentially [9][10] - Recurring patient sources represented 42% of fourth quarter revenue, up from 26% in the fourth quarter of 2024 [13][32] Market Data and Key Metrics Changes - The company signed in-network contracts with additional Medicare Advantage and commercial payers, including a multi-state agreement with Elevance Health covering 45 million lives [19][18] - The patient pipeline stood at 1,528 patients, an increase of 10% year-over-year [33][25] - The company faced challenges with Medicare Advantage payers, resulting in a decrease in authorizations and revenue from this segment [28][29] Company Strategy and Development Direction - The company aims to grow revenue through direct-to-patient marketing and expand orders from recurring sources [7][9] - A focus on managing cost structure and enhancing manufacturing processes to demonstrate operating leverage as the company scales [8][21] - Continued innovation in product development, including the launch of the MyoPro 2X and plans for the MyoPro 3 [46][39] - The strategic pivot towards recurring patient sources is expected to reduce customer acquisition costs and improve operating leverage [23][45] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the O&P channel and international markets [90][91] - The company anticipates a challenging environment with Medicare Advantage payers but is working to secure more payer contracts [29][62] - For 2026, the company expects revenue in the range of $43 million to $46 million, with a focus on recurring sources [43][45] - Management aims to reduce cash burn by approximately 50% in 2026 compared to 2025 [45][41] Other Important Information - The company is investing in R&D, including a randomized controlled trial to support the efficacy of MyoPro [23][104] - The MyoConnect program has generated over 100 qualified candidates in its first six months, contributing to the patient pipeline [12][11] - The company plans to activate the Myomo mobile app for patients and clinicians, which is expected to reduce costs [21][23] Q&A Session Summary Question: What drove the increase in cost per pipeline ad in the fourth quarter? - Management noted that higher advertising costs in the fourth quarter were due to competition with holiday advertising and election cycles [55] Question: Can you provide details on the O&P channel's performance? - The company reported over $1 million in revenue from the O&P channel, with approximately 36 units ordered in the fourth quarter [60] Question: What are the assumptions for the U.S. O&P business in 2026 guidance? - Growth in the O&P channel and international markets is expected to drive overall growth, while direct billing is anticipated to remain flat [61] Question: What is the current status of the pipeline ads and dropout rates? - The pipeline ads were lower due to a shutdown in the last days of 2025, and the dropout rate was affected by challenges in obtaining authorizations from Medicare Advantage [66][70] Question: How does the company plan to use data from the randomized controlled trial? - The data will be used to convince payers of the MyoPro's medical necessity and to support reimbursement efforts [104] Question: What is the expected gross margin for international operations compared to domestic? - International gross margins are expected to be slightly lower than domestic margins, but both will benefit from increased volume [110]